DAPAGLIFLOZIN VERSUS A DIPEPTIDYL PEPTIDASE 4 INHIBITOR (DPP4) BOTH ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM): IMPACT ON HEALTH, QUALITY OF LIFE AND COSTS IN THE TURKISH CLINICAL SETTING
dc.contributor.author | Malhan, S. | |
dc.contributor.author | Guler, S. | |
dc.contributor.author | Yetkin, I. | |
dc.contributor.author | Ignacio, T.J. | |
dc.contributor.author | Verheggen, B. | |
dc.contributor.author | Charokopou, M. | |
dc.date.accessioned | 2019-10-06T11:36:51Z | |
dc.date.available | 2019-10-06T11:36:51Z | |
dc.date.issued | 2015 | |
dc.identifier.issn | 1098-3015 | |
dc.identifier.uri | https://www.valueinhealthjournal.com/article/S1098-3015(15)04172-8/pdf | |
dc.identifier.uri | http://hdl.handle.net/11727/4055 | |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.1016/j.jval.2015.09.2096 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.title | DAPAGLIFLOZIN VERSUS A DIPEPTIDYL PEPTIDASE 4 INHIBITOR (DPP4) BOTH ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM): IMPACT ON HEALTH, QUALITY OF LIFE AND COSTS IN THE TURKISH CLINICAL SETTING | en_US |
dc.type | conferenceObject | en_US |
dc.relation.journal | VALUE IN HEALTH | en_US |
dc.identifier.volume | 18 | en_US |
dc.identifier.issue | 7 | en_US |
dc.identifier.startpage | A607 | en_US |
dc.identifier.endpage | A607 | en_US |
dc.identifier.wos | 000209861300568 | en_US |